Trials / Completed
CompletedNCT00831597
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Pharmatech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase II trial to evaluate the efficacy and safety of combination bendamustine and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. It is hypothesized that the BR combination will produce at least a 70% overall response rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bendamustine | 120 mg/m2 IV, Days 1, 2 of Cycles 1-6 |
| DRUG | rituximab | 375 mg/m2 IV, Day 1 of Cycles 1-6 |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2013-08-01
- Completion
- 2013-09-01
- First posted
- 2009-01-29
- Last updated
- 2016-04-19
Locations
33 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00831597. Inclusion in this directory is not an endorsement.